Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)

ELITE PHARMACEUTICALS INC /NV/

2026-Q1 EPS reported -$0.01 revenue$40,211,097

Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.
Operating profit rose 81% to $19.6M, driven by lisdexamfetamine products launched in FY2025 and Elite label product lines.
Conference call scheduled for July 1, 2025 at 11:30 AM EDT to discuss results and business update.
Company requests stockholder questions be submitted by 7:00 PM EDT on June 30, 2025.
No EPS or net income figures disclosed in the press release; full 10-K filed separately.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.